Choledocholithiasis resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 31: | Line 31: | ||
{{familytree/start |summary=Asymptomatic choledocholithiasis }} | {{familytree/start |summary=Asymptomatic choledocholithiasis }} | ||
{{familytree | | | | A01 | | | | A01= ''' | {{familytree | | | | A01 | | | | A01= <div style="float: left; text-align: left ">'''Incidental bile duct stones'''<br>❑ On noninvasive imaging for nonbiliary indications<BR>❑ During evaluation of symptomatic cholelithiasis<BR>❑ Intraoperatively during cholecystectomy </div>}} | ||
{{familytree | |,|-|-|^|-|-|.| }} | {{familytree | |,|-|-|^|-|-|.| }} | ||
{{familytree | B01 | | | | B02 | | | B01=CBD stones discovered<br> during imaging| B02=CBD stones discovered<br> during cholecystectomy}} | {{familytree | B01 | | | | B02 | | | B01'''=CBD stones discovered'''<br> '''during imaging'''| B02= '''CBD stones discovered'''<br> '''during cholecystectomy'''}} | ||
{{familytree | |!| | | |,|-|^|-|.| | }} | {{familytree | |!| | | |,|-|^|-|.| | }} | ||
{{familytree | C01 | | C02 | | C03 | C01= ❑ Preoperative [[ERCP]], and <br> CBD stone removal, and <br> ❑ Elective cholecystectomy| C02= ❑ Intraoperative CBD exploration <br> and stone removal| C03= ❑ Postoperative ERCP, and <br>CBD stone removal}} | {{familytree | C01 | | C02 | | C03 | C01= ❑ Preoperative [[ERCP]], and <br> CBD stone removal, and <br> ❑ Elective cholecystectomy| C02= ❑ Intraoperative CBD exploration <br> and stone removal| C03= ❑ Postoperative ERCP, and <br>CBD stone removal}} |
Revision as of 19:36, 21 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]
Definitions
Terms | Definitions |
---|---|
Choledocholithiasis (bile duct stones) | Choledocholithiasis are crystallized pieces of bile including cholesterol and bilirubin in the bile duct. It usually refers to the gallstones that have migrated into the biliary tract from the gallbladder. |
Primary choledocholithiasis | Primary choledocholithiasis are biliary tract stones resulting from biliary stasis and not from the migration of gallstones from the gallbladder into the biliary tract. |
Asymptomatic choledocholithiasis | Asymptomatic choledocholithiasis refers to the presence of stones in the bile duct, that might be detected during imaging studies of the abdomen, in the absence of any symptoms. |
Symptomatic and uncomplicated choledocholithiasis | Symptomatic and uncomplicated choledocholithiasis refers to the presence of stones in the bile duct that are associated with symptoms in the absence of complications such as acute cholangitis or pancreatitis. |
Symptomatic and complicated choledocholithiasis | Symptomatic and complicated choledocholithiasis refers to the presence of stones in the bile duct with symptoms and complications such as acute cholangitis or pancreatitis. |
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Management of Asymptomatic Choledocholithiasis
Shown below is a diagram depicting the management of choledocholithiasis according to American Society for Gastrointestinal Endoscopy (ASGE)[1] and American Gastroenterological Association (AGA).[2]
Incidental bile duct stones ❑ On noninvasive imaging for nonbiliary indications ❑ During evaluation of symptomatic cholelithiasis ❑ Intraoperatively during cholecystectomy | |||||||||||||||||||||||
{{{ B01 }}} | CBD stones discovered during cholecystectomy | ||||||||||||||||||||||
❑ Preoperative ERCP, and CBD stone removal, and ❑ Elective cholecystectomy | ❑ Intraoperative CBD exploration and stone removal | ❑ Postoperative ERCP, and CBD stone removal | |||||||||||||||||||||
Management of Symptomatic Choledocholithiasis
Characterize the symptoms: ❑ Symptomatic ❑ Aymptomatic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symptomatic: ❑ Abdominal pain | Asymptomatic: Bile duct stones discovered incidentally ❑ On noninvasive imaging for nonbiliary indications ❑ During evaluation of symptomatic cholelithiasis ❑ Intraoperatively during cholecystectomy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Acute or intermittent RUQ or epigastric pain ❑ Sharp, severe and steady pain ❑ Pain >6 hours ❑ Pain radiating to the right shoulder blade ❑ Pain radiating to the back ❑ Pain after food intake ❑ Jaundice ❑ Pale stools ❑ Dark urine ❑ Fever ❑ Nausea & vomiting ❑ Diaphoresis ❑ Altered mental status ❑ history of recurrent symptoms ❑ history of previous GB disease | Asymptomatic choledocholithiasis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Altered mental status ❑ Fever ❑ Dehydration ❑ Jaundice ❑ Hypotension ❑ Tachycardia ❑ Dyspnea ❑ Hypoxemia ❑ Abdominal tenderness | CBD stones discovered during imaging | CBD stones discovered during cholecystectomy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order laboratory tests: ❑ CBC ❑ BMP ❑ CRP ❑ Total bilirubin ❑ Direct bilirubin ❑ Albumin ❑ AST ❑ ALT ❑ Alkaline phosphatase ❑ GGT ❑ Amylase ❑ Lipase | Preoperative ERCP & CBD stone removal, & elective cholecystectomy | Intraoperative CBD exploration & stone removal or postoperative ERCP & CBD stone removal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Suspect symptomatic choledocholithiasis:
Symptomatic & uncomplicated choledocholithiasis: ❑ Acute or intermittent RUQ or epigastric pain, >6 hours & associated w/ nausea & vomiting ❑ Elevated bilirubin, alkaline phosphatase and GGT levels | Symptomatic & complicated choledocholithiasis: Features of symptomatic & uncomplicated choledocholithiasis w/ Acute cholangitis: Biliary pancreatitis: ❑ Elevated amylase & lipase | Consider severity assessment & management for acute cholangitis & biliary pancreatitis accordingly | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order transabdominal USG (TAUSG) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnostic predictors:[1] Very strong: ❑ Bilirubin >4 mg/dL ❑ CBD stone on TAUSG ❑ Clinical ascending cholangitis
Strong: ❑ Bilirubin 1.8-4 mg/dL ❑ Dilated CBD (>6 mm with GB in situ) on TAUSG Moderate: ❑ Age >55 years ❑ Abnormal LFT other than bilirubin (elevated alkaline phosphatase & GGT) ❑ Clinical biliary pancreatitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No predictors | One strong and/or at least one moderate predictor | Presence of any very strong or both strong predictors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk | Intermediate risk | High risk | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GBS or biliary sludge seen during TAUSG | Laparoscopic IOC or US | Preoperative EUS/MRCP | CBD stones present or test unavailable | Preoperative ERCP & CBD stone removal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cholecystectomy w/o preoperative EUS/MRCP or intraoperative cholangiography/US/CBD exploration | CBD stones present | CBD stones absent | If GBS or sludge seen during imaging | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intraoperative CBD exploration & stone removal | Postoperative ERCP & CBD stone removal | Elective cholecystectomy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
†ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMP: Basic Metabolic Profile; CBC: Complete Blood Count; CBD: Common Bile Duct; CRP: C-reactive protein; ERCP: Endoscopic retrograde cholangiopancreatography; EUS: Endoscopic ultrasound; GB: Gallbladder; GBS: Gallbladder stone; GGT: Gamma-glutamyl transpeptidase; IOC: Intraoperative cholangiography; LFT: Liver function tests; MRCP: Magnetic resonance cholangiopancreatography; RUQ: Right Upper Quadrant; Sx: Symptom; US: Ultrasound; W/: With; W/O: Without
Do's
- Initial evaluation of suspected choledocholithiasis should include serum liver biochemical tests and a transabdominal ultrasound of the right upper quadrant. These tests should be used to risk-stratify patients to guide further evaluation and management (Grade B).
- EUS or MRCP can be considered in the diagnostic evaluation of postcholecystectomy patients suspected of having choledocholithiasis when initial laboratory and ultrasonography data are abnormal yet non diagnostic (Grade C).
- Sphincter of Oddi dysfunction should be considered as a differential diagnosis if EUS or MRCP did not detect any stones in the bile duct of postcholecystectomy patients suspected of having choledocholithiasis.
- Laparoscopic cholecystectomy is preferred over open but conversion to open may be necessary and should not be considered a failure in management.[3]
Dont's
- Laparoscopic cholecystectomy is contraindicated in untreated coagulopathy, lack of equipment, lack of surgeon expertise, hostile abdomen, advanced cirrhosis/liver failure, and suspected gallbladder cancer.
Grade System for Rating the Quality of Evidence
The grade system for rating the quality of evidence is as follows.[4]
Quality of evidence | Definition |
---|---|
High quality (Grade A) | Further research is very unlikely to change our confidence in the estimate of effect. |
Moderate quality (Grade B) | Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. |
Low quality (Grade C) | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
Very low quality (Grade D) | Any estimate of effect is very uncertain. |
References
- ↑ 1.0 1.1 Maple, JT.; Ben-Menachem, T.; Anderson, MA.; Appalaneni, V.; Banerjee, S.; Cash, BD.; Fisher, L.; Harrison, ME.; Fanelli, RD. (2010). "The role of endoscopy in the evaluation of suspected choledocholithiasis". Gastrointest Endosc. 71 (1): 1–9. doi:10.1016/j.gie.2009.09.041. PMID 20105473. Unknown parameter
|month=
ignored (help) - ↑ Carr-Locke, DL. (2006). "Cholelithiasis plus choledocholithiasis: ERCP first, what next?". Gastroenterology. 130 (1): 270–2. doi:10.1053/j.gastro.2005.12.010. PMID 16401489. Unknown parameter
|month=
ignored (help) - ↑ Duncan, CB.; Riall, TS. (2012). "Evidence-based current surgical practice: calculous gallbladder disease". J Gastrointest Surg. 16 (11): 2011–25. doi:10.1007/s11605-012-2024-1. PMID 22986769. Unknown parameter
|month=
ignored (help) - ↑ Overby, DW.; Apelgren, KN.; Richardson, W.; Fanelli, R.; Overby, DW.; Apelgren, KN.; Beghoff, KR.; Curcillo, P.; Awad, Z. (2010). "SAGES guidelines for the clinical application of laparoscopic biliary tract surgery". Surg Endosc. 24 (10): 2368–86. doi:10.1007/s00464-010-1268-7. PMID 20706739. Unknown parameter
|month=
ignored (help)